8-K: Zomedica Announces Q1 2025 Financial Results: Revenue Up 4% to $6.5 Million, Gross Margin Strong at 68%

Zomedica reports a 4% increase in revenue to $6.5 million for Q1 2025, driven by strong consumable sales and international growth, while maintaining a robust 68% gross margin.

Summary

• Zomedica Corp. reported its financial results for the first quarter ended March 31, 2025.
• Revenue for the quarter reached $6.5 million, a 4% increase compared to the first quarter of 2024.
• Consumable revenues grew by 13% to $4.5 million, driven by TRUFORMA and PulseVet products.
• International sales increased by 32% compared to Q1 2024.
• Gross margin was 68%, compared to 66% in the first quarter of 2024.
• The company reported a net loss of $63.8 million, which includes a non-cash impairment charge of $55.8 million due to a decline in the company's market capitalization.
• Adjusted Non-GAAP EBITDA loss was $5.7 million, compared to $5.3 million for the first quarter of 2024.
• Zomedica had $64.6 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2025.
• As of March 31, 2025, Zomedica had 979,949,668 common shares issued and outstanding.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue and gross margin improved, a significant net loss due to an impairment charge tempers the positive aspects. The company's future outlook is optimistic, but risks remain.

Positives

• Revenue increased by 4% to $6.5 million.
• Consumable revenues grew by 13% due to strong performance of TRUFORMA and PulseVet products.
• International sales increased by 32% compared to the first quarter of 2024.
• Gross margin improved to 68% from 66% in the first quarter of 2024.
• Adjusted operating expenses decreased by 9% compared to the first quarter of 2024.
• The company has $64.6 million in liquidity to support growth.

Negatives

• The company reported a net loss of $63.8 million for the quarter.
• The net loss includes a non-cash impairment charge of $55.8 million.
• Capital revenues were down 12% from the first quarter of 2024.
• Diagnostics segment revenue was down 25% over the first quarter of 2024.

Risks

• The company's market capitalization decline triggered a significant non-cash impairment charge.
• The company's future performance is subject to various risks and uncertainties, including those related to clinical studies, regulatory approvals, and competition.
• The company's forward-looking statements are subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those anticipated in the forward-looking information.

Future Outlook

Zomedica believes it is well-positioned to aggressively execute its strategy to drive the accelerated adoption of its innovative portfolio on a global scale, supported by the strength of its balance sheet.

Management Comments

• 'We are pleased with our performance in the first quarter as we posted record year over year revenue for the 17th straight quarter,' said Larry Heaton, President and Chief Executive Officer of Zomedica.
• Mr. Heaton stated that the company's performance was bolstered by continued and robust usage of consumable PulseVet products and the continued growth and adoption of TRUFORMA products.
• Mr. Heaton concluded that the company is well-positioned to aggressively execute its strategy to drive the accelerated adoption of its innovative portfolio on a global scale.

Industry Context

Zomedica operates in the veterinary health market, which is experiencing growth due to increasing pet ownership and spending on pet care. The company's focus on point-of-care diagnostics and therapeutics aligns with the trend towards faster and more convenient veterinary services.

Comparison to Industry Standards

• It is difficult to compare Zomedica directly to industry standards without more specific information on its competitors and their financial performance.
• However, a 68% gross margin is generally considered strong in the medical device industry.
• Companies like IDEXX Laboratories and Zoetis are major players in the animal health market, but their product portfolios and business models differ significantly from Zomedica's.

Stakeholder Impact

• Shareholders will be concerned about the net loss and the impact of the impairment charge on the company's financial performance.
• Employees may be affected by the company's efforts to optimize its commercial organization.
• Veterinarians and pet owners may benefit from the company's innovative therapeutic and diagnostic solutions.

Next Steps

• Zomedica will continue to focus on expanding its product portfolio and optimizing its commercial organization.
• The company plans to drive the accelerated adoption of its innovative portfolio on a global scale.
• Zomedica will host a conference call to discuss the company's operational and financial highlights for its first quarter ended March 31, 2025.

Key Dates

Keywords

Zomedica, financial results, Q1 2025, revenue, gross margin, veterinary, diagnostics, therapeutics, PulseVet, TRUFORMA, VETIGEL, consumables, international sales